Radiopharmaceuticals Market Size, Growth and Value Analysis 2028

Radiopharmaceuticals Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type (Diagnostic Nuclear Medicine and Therapeutic Nuclear Medicine), Product Type (Technetium-99m, Thallium-201, Gallium-67, Iodine-131, Copper-64, and Other), Application (Oncology, Cardiology, Neurology, and Others), and End User (Hospitals, Imaging Centers, Academic and Research Centers, and Others)

Publication Month : Aug 2021

  • Report Code : TIPRE00003751
  • Category : Pharmaceuticals
  • Status : Published
  • No. of Pages : 220
Inquire Before Buy

PRICING

$4550

$2730

The radiopharmaceuticals market is projected to reach US$ 13,818.17 million by 2028 from US$ 7,550.74 million in 2021; it is expected to grow at a CAGR of 9.0% from 2021 to 2028.

The growth of the market is attributed to the rising prevalence of chronic diseases, suitability of alpha radioimmunotherapy in targeted cancer treatment, and advancements in nuclear imaging techniques. However, the short shelf-life of radiopharmaceuticals and availability of substitutes restrain the Radiopharmaceuticals market growth. A radiopharmaceutical is a drug that can be used either for diagnostic or therapeutic purposes. Radiopharmaceuticals are radioisotopes that are bound to biological molecules that target specific tissues, organs, or cells within the human body. Radioisotopes emitting gamma rays are useful for diagnostic imaging where the radiation escapes the body. These rays are detected by a specific device, which is usually single-photon emission computed tomography (SPECT)/positron emission tomography (PET) cameras.

The COVID-19 pandemic has profoundly changed hospital activities, including nuclear medicine (NM) practices across Europe. A literature search on PubMed was performed covering COVID-19 studies published up until January 2021. As per the findings, the pandemic strongly challenged NM departments, and a reduction in the workforce has been experienced in every center in Europe. To limit COVID-19 transmission, NM departments introduced restriction measures, such as the rescheduling of non-high-priority procedures. Also, a few of the departments experienced a delay in radiopharmaceuticals supply or technical assistance due to the pandemic. As a result, the crisis resulted in a significant reduction of diagnostic and therapeutic NM procedures and a reduced level of care for patients affected by diseases, such as cancer or acute cardiovascular disease.

Lucrative Regions for Radiopharmaceuticals Market

Lucrative Regions for Radiopharmaceuticals Market
  • Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
  • Request discounts available for Start-Ups & Universities

Market Insights

Rising Prevalence of Chronic Diseases Fuels Radiopharmaceuticals Market Growth

The prevalence of chronic diseases such as cardiovascular diseases (CVDs), cancer, chronic lung diseases, stroke, Alzheimer’s disease, chronic kidney disease, and several neurological disorders is increasing rapidly across the world. These diseases are among the leading causes of death. As per the World Health Organization (WHO), cancer accounted for 10 million deaths in 2020 globally. Furthermore, as per the estimations of the American Cancer Society, 1,806,590 new cases of cancer were diagnosed in the US in 2020. As per the European Heart Network, CVDs cause 3.9 million deaths in Europe and more than 1.8 million deaths in the European Union (EU) every year. They account for 45.0% of total mortalities in Europe and 37.0% of the total death count in the EU. As per the American College of Cardiology, CVDs cause 800,000 death cases in the US every year. Coronary heart disease (CHD) contributes to a majority of CVD mortalities, followed by stroke and heart failure; 90 million Americans are diagnosed with CVDs per year. In addition, CVDs contribute to 31% of total death globally, and the cost burden of CVDs on healthcare systems is expected to be US$ 1,044 billion by 2030.

According to Emory Healthcare, in 2018, 5 million people suffer from congestive heart failure (CHF) in the US. Further, according to the WHO, ~1.71 billion people in the world are suffering from musculoskeletal conditions. An effective examination is a must for the treatment of chronic diseases, and nuclear substances are used for diagnosis and examination purposes; they are used in diagnostic tests such as positron emission tomography (PET) and single-photon emission computerized tomography (SPECT). Thus, with a surge in the incidence of chronic diseases, the need for radiopharmaceuticals is also increasing, thereby driving the market growth.

Type-Based Insights

Based on type, the radiopharmaceuticals market is bifurcated into diagnostic nuclear medicine and therapeutic nuclear medicine. The diagnostic nuclear medicine segment is holding a larger share of the market and is expected to register a higher CAGR during 2021–2028. The radioisotope used widely in diagnostic nuclear medicine is technetium-99m. The radioisotope attaches to several specific molecules, allowing the diagnosis of various diseases, such as the certain types of cancers. For instance, technetium-99m-MDP (methylene diphosphonate) is widely used to detect bone metastasis associated with cancer.

Radiopharmaceuticals Market, by Type – 2021 and 2028

Radiopharmaceuticals Market, by Type – 2021 and 2028
  • Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
  • Request discounts available for Start-Ups & Universities

Product Type-Based Insights

Based on product type, the radiopharmaceuticals market is segmented into Technetium-99m, Thallium-201, Gallium-67, Iodine-131, Copper-64, and other. The Technetium-99m segment is holding the largest share of the market, whereas the gallium-67 segment is expected to register the highest CAGR during 2021–2028. Gallium-67 is used for the imaging and localization of inflammatory lesions (infections). Gallium-67 is an injectable radiopharmaceutical that is used with single photon emission computed tomography (SPECT) to detect the presence of acute inflammatory lesions and various malignancies, such as Hodgkin’s disease, lymphomas, and bronchogenic carcinomas.

Application-Based Insights

Based on application, the radiopharmaceuticals market is segmented into oncology, cardiology, neurology, and others. The oncology segment is holding the largest share of the market. The market growth for this segment can be attributed to the increasing incidence of cancer worldwide. Cancer is one of the significant health problems with a high mortality rate. It is a threat to global health. As per the WHO, in 2018, an estimated 18 million new cancer cases were diagnosed worldwide, and 9.6 million people died from cancer. However, the market for the cardiology segment is expected to grow at the fastest rate in the coming years.

End User-Based Insights

Based on end user, the radiopharmaceuticals market is segmented into hospitals, imaging centers, academic and research centers, and others. In 2021, the hospitals segment is holding the largest share of the market. The market growth for this segment can be attributed to the rising prevalence of chronic diseases, increasing number of hospitals across the world, and rapidly growing number of surgical procedures. However, the market for the diagnostic centers segment is expected to grow at the fastest rate in the coming years.


Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Radiopharmaceuticals Market: Strategic Insights

radiopharmaceuticals-market
Market Size Value inUS$ 7,550.74 Million in 2021
Market Size Value byUS$ 13,818.17 Million by 2028
Growth rateCAGR of 9.0% from 2021-2028
Forecast Period2021-2028
Base Year2021
Analyst Image

Akshay

Have a question?

Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

Analyst Image  Speak to Analyst

Companies operating in the radiopharmaceuticals market are adopting the product innovations strategy to meet the evolving customer demands across the world, which also permits them to maintain their brand name in the global market.

Radiopharmaceuticals Market – by Type

  • Diagnostic Nuclear Medicine 
    • SPECT Radiopharmaceuticals
    • PET Radiopharmaceuticals
  • Therapeutic Nuclear Medicine
    • Alpha Emitters
    • Beta Emitters
    • Brachytherapy Isotopes

Radiopharmaceuticals Market – by Product Type

  • Technetium-99m
  • Thallium-201
  • Gallium-67
  • Iodine-131
  • Copper-64
  • Other

Radiopharmaceuticals Market – by Application

  • Oncology
  • Cardiology
  • Neurology
  • Others

Radiopharmaceuticals Market – by End User

  • Hospitals
  • Imaging Centers
  • Academic and Research Centers
  • Others

Radiopharmaceuticals Market– by Geography

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • France
    • Germany
    • Italy
    • UK
    • Spain
    • Rest of Europe
  • Asia Pacific (APAC)
    • China
    • India
    • South Korea
    • Japan
    • Australia
    • Rest of APAC
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • UAE
    • Rest of MEA
  • South and Central America (SCAM)
    • Brazil
    • Argentina
    • Rest of SCAM

Company Profiles

  • Cardinal Health
  • GE Healthcare
  • Curium
  • Lantheus Medical Imaging
  • Bayer AG
  • Bracco Imaging
  • Eczacýbaþý-Monrol Nuclear Products
  • Nordion
  • Advanced Accelerator Applications
  • NTP Radioisotopes
Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

Type , Product Type , Application , and End User

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

Argentina, Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, RoAPAC, RoE, RoMEA, RoSCAM, Saudi Arabia, South Africa, South Korea, Spain, United Arab Emirates, United Kingdom, United States

Frequently Asked Questions


What are radiopharmaceuticals?

Radiopharmaceuticals are radioisotopes that are bound to biological molecules that target specific tissues, organs, or cells within the human body. Radioisotopes emitting gamma rays are useful for diagnostic imaging where the radiation escapes the body. These rays are detected by a specific device, which is usually single-photon emission computed tomography (SPECT)/ positron emission tomography (PET) cameras.

What are the driving factors for the radiopharmaceuticals market across the globe?

The factors that are driving growth of the market are rising prevalence of chronic diseases, suitability of alpha radioimmunotherapy in targeted cancer treatment, and advancements in nuclear imaging techniques.

Who are the developments carrying out by major players in the radiopharmaceuticals market?

Various companies have made organic growth strategies in the Radiopharmaceuticals Market. Some of the activities undertaken by the company, which have promoted its growth are, launches, enhancements and expansion & relocation activities. Companies such as Lantheus Medical Imaging, Inc., Bracco Imaging S.p.A, Advanced Accelerator Applications amongst others are some of the companies that have been implementing various organic strategies that have helped the growth of the company.

Which region is dominated the radiopharmaceuticals market?

North America dominates the global radiopharmaceuticals market due to factors such as technological advancement, increasing product launches, well-developed healthcare facility centres equipped with modern-age equipment and instruments.

Which segment is growing at the highest CAGR in the radiopharmaceuticals market?

The diagnostic nuclear medicine segment is growing at the highest CAGR owing to availability of diagnostic devices and ease offered by these devices for diagnosis of various disorders. Also, nuclear medicine provides better diagnostic information about the functioning of a specific organ, as it uses radiation.

Which region is the fastest growing in the radiopharmaceuticals market?

Asia Pacific is expected to be the fastest growing region in the radiopharmaceuticals market. The growth of the market in this region is primarily due to prevalence of stroke and other neurological disorders along with the presence of supportive government initiatives and research in the field of radiopharmaceuticals.

The List of Companies - Radiopharmaceuticals Market

  1. Cardinal Health
  2. GE Healthcare
  3. Curium
  4. Lantheus Medical Imaging
  5. Bayer AG
  6. Bracco Imaging
  7. Eczacýbaþý-Monrol Nuclear Products
  8. Nordion
  9. Advanced Accelerator Applications
  10. NTP Radioisotopes

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • 3.1 Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • 3.2 Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • 3.3 Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • 3.4 Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Trends and growth analysis reports related to Radiopharmaceuticals Market